References
- Kloosterhof NK, De Rooi JJ, Kros M, et al. Molecular subtypes of glioma identified by genome-wide methylation profiling. Gene Chromosomes Cancer. 2013;52(7):665–674.
- Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33(25):2735–2744.
- Pinel B, Duchesne M, Godet J, et al. Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide. J Neurooncol. 2017;132(2):287–294.
- Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
- Taylor LP. Diagnosis, treatment, and prognosis of glioma: five new things. Neurology. 2010;75(18 Suppl 1):S28–32.
- Ma X, Yoshimoto K, Guan Y, et al. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro-Oncology. 2012;14(9):1153–1162.
- Ehtesham M, Min E, Issar NM, et al. The role of the CXCR4 cell surface chemokine receptor in glioma biology. J Neurooncol. 2013;113(2):153–162.
- Zheng X, Xie Q, Li S, et al. CXCR4-positive subset of glioma is enriched for cancer stem cells. Oncol Res. 2011;19(12):555–561.
- Yf P, Xh Y, Jy J, et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol. 2011;224(3):344–354.
- Yadav V, Zamler D, Baker GJ, et al. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: a genetic knockdown study. Oncotarget. 2016;7(50):83701–83719.
- Lv S, Sun B, Zhong X, et al. The clinical implications of chemokine receptor cxcr4 in grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):555–561.
- Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522.
- Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69(23):9065–9072.
- Gagliardi F, Narayanan A, Reni M, et al. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia. 2014;62(7):1015–1023.
- Xu C, Zhao H, Chen H, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–4964.
- Micucci C, Matacchione G, Valli D, et al. HIF2alpha is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer. 2015;113(8):1178–1185.
- Sakao K, Vyas AR, Chinni SR, et al. CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells. Cancer Prevent Res. 2015;8(5):365–374.
- Richardson PJ. CXCR4 and glioblastoma. Anticancer Agents Med Chem. 2016;16(1):59–74.
- Wurth R, Bajetto A, Harrison JK, et al. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci. 2014;8:144.
- Yoshimoto K, Ma X, Guan Y, et al. Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol. 2011;28(4):291–296.
- Ehtesham M, Mapara KY, Stevenson CB, et al. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett. 2009;274(2):305–312.
- Yao C, Li P, Song H, et al. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma. Mol Neurobiol. 2016;53(6):3948–3953.
- Zhu Y, Yang P, Zhang X, et al. The effect and mechanism of CXCR4 silencing on metastasis suppression of human glioma U87 cell line. Anatomical Record. 2013;296(12):1857–1864.
- Calinescu AA, Yadav VN, Carballo E, et al. Survival and proliferation of neural progenitor-derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine-positive feedback mechanism. Clinical Cancer Res. 2017;23(5):1250–1262.
- Park SA, Ryu CH, Kim SM, et al. CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int J Oncol. 2011;38(1):97–103.
- Mercurio L, Ajmone-Cat MA, Cecchetti S, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016;35:55.
- Tang W, Wang X, Chen Y, et al. CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection. Pathol Biol (Paris). 2015;63(4–5):190–198.
- Esencay M, Newcomb EW, Zagzag D. HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol. 2010;99(1):33–40.
- Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest. 2006;86(12):1221–1232.
- Shinawi T, Hill VK, Krex D, et al. DNA methylation profiles of long- and short-term glioblastoma survivors. Epigenetics. 2013;8(2):149–156.